Latest Healthcare It News

HealthCo Healthcare & Wellness REIT reported a solid 5% increase in Funds From Operations (FFO) and Distribution Per Unit (DPU) for the first half of FY25, underpinned by stable asset valuations and a robust healthcare portfolio.

Cochlear Limited has announced a fully franked dividend of AUD 2.15 per share for the six months ending December 2024, payable in multiple currencies on April 14, 2025.

HealthCo Healthcare & Wellness REIT reports solid 5% growth in FFO and DPU for 1H FY25, maintaining strong occupancy and gearing levels despite ongoing Healthscope lease speculation.

HealthCo Healthcare and Wellness REIT reported a sharp increase in half-year losses to $15.4 million, alongside a portfolio reduction and steady funds from operations, highlighting a complex transition phase.

Pro Medicus has delivered a record first half in FY25, driven by strong revenue growth, major contract wins, and successful implementations that position it well for future expansion.

Pro Medicus Limited has announced a fully franked ordinary dividend of AUD 0.25 per share for the six months ending December 2024, signaling continued shareholder returns without the need for external approvals.

Pro Medicus Limited has delivered a record interim profit of $51.7 million, boosted by major North American contract wins and strong margin expansion.

Pro Medicus Limited delivered a robust half-year performance ending December 2024, with after-tax profits soaring 42.7% to $51.74 million and revenues climbing 31.1% to $97.2 million, driven by significant contract wins in North America and sustained growth in Australia.

Pro Medicus Limited has reported a robust half-year financial performance for the period ending December 31, 2024, with net profit soaring 42.7% and an increased interim dividend declared.

Micro-X Limited has initiated a $2.7 million retail entitlement offer as part of a broader $6 million capital raising, supporting its strategic pivot towards medical imaging technologies and strengthening its balance sheet.

ASX Limited has reported a robust first half of FY25 with record operating revenue and a near 10% rise in underlying net profit, underpinned by strong growth across key business segments and a strategic focus on technology modernization.

Telix Pharmaceuticals has gained UK MHRA approval for Illuccix, its advanced prostate cancer PET imaging agent, promising to alleviate supply shortages and improve diagnostic accuracy across the UK.